Editas Medicine, Inc. — Director's Dealing 2017

Oct 4, 2017

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Editas Medicine, Inc. (EDIT)
CIK: 0001650664
Period of Report: 2017-10-02

Reporting Person: Bosley Katrine (Director, President and CEO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2017-10-02	Common Stock	S	8133	$24.7706	Disposed	1399630	Direct
2017-10-02	Common Stock	S	200	$25.33	Disposed	1399430	Direct

Footnotes

F1: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person on March 17, 2017.

F2: This transaction was executed in multiple trades at prices ranging from $24.2 to $25.17. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected

F3: This transaction was executed in multiple trades at prices ranging from $25.32 to $25.34. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected